Sugi Predict

Sugi Predict / Compounds / SCHEMBL1900607

SCHEMBL1900607

SCHEMBL1900607

CC1(C)OB(c2cccc3c2CCCC3)OC1(C)C

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ BCL2L1 Q07817 1/20 0.42
▸ BAD Q92934 1/20 0.42
▸ P2RX7 Q99572 1/20 0.39
▸ LPL P06858 3/20 0.35
▸ LIPG Q9Y5X9 3/20 0.35
▸ TSHR P16473 2/20 0.34
▸ ALDH1A1 P00352 4/20 0.34
▸ MAPK1 P28482 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ THRA P10827 1/20 0.33
▸ THRB P10828 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ CCR4 P51679 1/20 0.33
▸ JAK2 O60674 2/20 0.32
▸ BTK Q06187 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12667047 0.97 P2RX7 (0.39) BCL2L1BADP2RX7LPLLIPG
SCHEMBL30768992 0.90 LPL (0.37) P2RX7LPLLIPGALDH1A1MAPK1
SCHEMBL15592746 0.89 BCL2L1 (0.41) BCL2L1BADTSHRALDH1A1MEN1
SCHEMBL26199528 0.81 BCL2L1 (0.38) BCL2L1BADTSHRALDH1A1MEN1
SCHEMBL31394843 0.80 MAPK1 (0.41) P2RX7LPLLIPGMAPK1
SCHEMBL31394907 0.80 MAPK1 (0.41) P2RX7LPLLIPGMAPK1
SCHEMBL31394538 0.80 MAPK1 (0.41) P2RX7LPLLIPGMAPK1
SCHEMBL31394111 0.80 MAPK1 (0.41) P2RX7LPLLIPGMAPK1
SCHEMBL29432478 0.78 CYP2A6 (0.40) P2RX7LPLLIPGMAPK1JAK2
SCHEMBL16760796 0.78 CD44 (0.47) P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630566-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2026-05-19 — — US disclosed
US-20240309020-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2024-09-19 — — US disclosed
US-11964989-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2024-04-23 — — US disclosed
CN-114615981-B KRAS G12D inhibitors 米拉蒂治疗股份有限公司 2024-04-12 — — CN disclosed
EP-4269405-A1 PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUND AS KRAS INHIBITOR Shanghai Kechow Pharma, Inc. (CN) 2023-11-01 — — EP disclosed
US-20230279025-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2023-09-07 — — US disclosed
US-20230279025-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2023-09-07 — — US disclosed
US-20230077225-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. 2023-03-09 — — US disclosed
US-11453683-B1 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2022-09-27 — — US disclosed
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 — — US disclosed
US-8298683-B2 Chromophore is a polycyclic aromatic hydrocarbon is selected from among anthracene, naphthalene, pyrene, rubrene and perylene; organic layer and electrodes laminated successively LG CHEM, LTD. (KR) 2012-10-30 — — US disclosed
EP-2316905-A1 Organic compound and organic light emitting device using the same LG Chem, Ltd. (KR) 2011-05-04 — — EP disclosed
US-20110003795-A1 Substituted Aromatic Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands GRUENENTHAL GMBH (DE) 2011-01-06 — — US disclosed
US-20110003795-A1 Substituted Aromatic Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands GRUENENTHAL GMBH (DE) 2011-01-06 — — US disclosed
WO-2010127855-A1 SUBSTITUTED AROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS Grünenthal GmbH (DE) 2010-11-11 — — WO disclosed
EP-1943323-A1 NEW ORGANIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING THE SAME LG Chem, Ltd. (KR) 2008-07-16 — — EP disclosed
WO-2007061181-A1 NEW ORGANIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING THE SAME LG CHEM. LTD. (KR) 2007-05-31 — — WO disclosed
US-20070059556-A1 Organic compound and organic light emitting device using the same LG CHEM. LTD. (KR) 2007-03-15 — — US disclosed
US-20070059556-A1 Organic compound and organic light emitting device using the same LG CHEM. LTD. (KR) 2007-03-15 — — US disclosed
US-20070059556-A1 Organic compound and organic light emitting device using the same LG CHEM. LTD. (KR) 2007-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003795-A1 Substituted Aromatic Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands TRPV1, UTS2R, CNR2 BCL2L1 4188/4885BAD 1058/4885P2RX7 38/4885
US-20230279025-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS BCL2L1 226/4885BAD 231/4885P2RX7 4172/4885
US-20230077225-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS BCL2L1 232/4885BAD 212/4885P2RX7 4144/4885
US-12630566-B2 KRas G12D inhibitors KRAS, NRAS, HRAS BCL2L1 514/4885BAD 796/4885P2RX7 4058/4885
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT BCL2L1 3886/4885BAD 3443/4885P2RX7 3800/4885
US-20070059556-A1 Organic compound and organic light emitting device using the same SLCO4C1, TRPA1, OR51E2 BCL2L1 3932/4885BAD 2521/4885P2RX7 404/4885
US-11964989-B2 KRas G12D inhibitors KRAS, NRAS, HRAS BCL2L1 159/4885BAD 164/4885P2RX7 4614/4885
US-11453683-B1 KRas G12D inhibitors KRAS, NRAS, HRAS BCL2L1 154/4885BAD 167/4885P2RX7 4608/4885
US-20240309020-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS BCL2L1 232/4885BAD 212/4885P2RX7 4144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.